Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in Pediatric KIT/PDGFRA-Dependent Solid Tumors
2023-508617-16-00Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of avapritinib in Nonhematologic neoplasms, diffuse midline glioma (DMG) and central nervous system tumor, sponsored by Blueprint Medicines. Primary endpoints: Part 1: Determination of the Part 2 recommended dose based on dose-limiting toxicity (DLT), Part 1: Incidence and severity of adverse events and 1 more. Started May 2024; status: completed.
02
Drugs
avapritinib
03
Conditions
Nonhematologic neoplasmsdiffuse midline glioma (DMG)central nervous system tumor
Beyond the preview
Go deeper on 2023-508617-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508617-16-00.